BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/26/2022 11:31:46 AM | Browse: 696 | Download: 2955
Publication Name World Journal of Clinical Infectious Diseases
Manuscript ID 77094
Country United States
ISSN 2220-3176 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Retrospective Cohort Study
Article Title Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota
Manuscript Source Unsolicited Manuscript
All Author List Bakir Dzananovic, Mark Williamson, Casmiar Nwaigwe and Chittaranjan Routray
Funding Agency and Grant Number
Corresponding Author Chittaranjan Routray, MD, Clinical Assistant Professor (Honorary), Family Medicine, University of North Dakota School of Medicine and Health Sciences, Minot, ND 58701, United States. routrayc@gmail.com
Key Words COVID-19; SARS-CoV-2 IgG-N; Anti-nucleocapsid IgG; Cytokines
Core Tip We intended to study an immunologic marker to predict the need for advanced oxygen supplement system and clinical outcome in order to support our hospital crisis management system during the peak of the pandemic. Our study demonstrated that presence of anti-nucleocapsid-IgG (IgG-N) against severe acute respiratory syndrome coronavirus 2 infection had no impact on the clinical outcome or disease severity in hospitalized coronavirus disease 2019 (COVID-19) patients. We did not find a correlation of statistical significance to use IgG-N as a biomarker to predict clinical outcome in COVID-19 patients admitted to a community hospital in North Dakota.
Publish Date 2022-09-26 10:18
Citation Dzananovic B, Williamson M, Nwaigwe C, Routray C. Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. World J Clin Infect Dis 2022; 12(2): 50-60
URL https://www.wjgnet.com/2220-3176/full/v12/i2/50.htm
DOI https://dx.doi.org/10.5495/wjcid.v12.i2.50
Full Article (PDF) WJCID-12-50.pdf
Full Article (Word) WJCID-12-50.docx